CharmHealth Internship Program Develops Future Healthtech Leaders
CharmHealth, a top provider of healthcare technology solutions, has introduced its inaugural internship program designed to cultivate the next generation of healthtech leaders. This paid internship offers participants hands-on experience and insight into various facets of the healthcare field. The…
Prothena Reports Q2 2024 Financials and Key Highlights
Prothena Corporation plc (NASDAQ:PRTA), a leader in protein dysregulation-based therapies, reported its financial results for Q2 and the first half of 2024, alongside key business updates. Second Quarter and 2024 Highlights: Pipeline Updates: Financial Guidance Update:Prothena expects 2024 net cash…
Insulet Reports 23% Revenue Growth for Q2 2024
Insulet Corporation (NASDAQ: PODD), a global leader in tubeless insulin pump technology with its Omnipod® products, today announced its financial results for the quarter ending June 30, 2024. Second Quarter Financial Highlights: Recent Strategic Highlights: Jim Hollingshead, President and CEO,…
PhotoPharmics Enrolls 100 Participants in Innovative Parkinson’s Trial
PhotoPharmics, a leader in phototherapy for neurodegenerative diseases, has announced the enrollment of the first 100 participants in its Light for PD clinical trial. This milestone is a key step in assessing Celeste, the company’s FDA Breakthrough light therapy device…
Nucleus Biologics Unveils QuickStart Media™: Optimized Formulations for Faster Therapy Optimization
Nucleus Biologics, The Cell Performance Company™, a top provider of custom cell culture media and buffers for the cell and gene therapy sector, is excited to introduce its new QuickStart Media™ platform. This innovative platform accelerates the formulation and manufacturing…
Verastem Oncology Reports Q2 2024 Financials and Business Updates
Verastem Oncology, a biopharmaceutical firm dedicated to developing new cancer treatments, has provided an update on its business activities and financial performance for the second quarter ended June 30, 2024. Dan Paterson, the company’s President and CEO, highlighted significant advancements:…
Pulse Biosciences Reports Success in First-in-Human Study of Nano-PFA Cardiac Surgery System
Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced that it successfully treated the first two patients in its initial human feasibility study using its innovative Cardiac Surgery System. This study, which employs the company’s proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology,…
Health Insurers Use Information Requests to Delay Billions in Payments, Kodiak Solutions Data Shows
According to a new quarterly revenue cycle benchmarking report from Kodiak Solutions, health insurers are increasingly using requests for additional information to initially deny claims from hospitals, health systems, and medical practices. This practice is leading to significant delays in…
Apyx Medical Announces Study Comparing Renuvion with Competing Technology in Liposuction
Apyx Medical Corporation (NASDAQ: APYX), the maker of the Renuvion® helium plasma and radiofrequency platform, has announced a peer-reviewed article in Plastic and Reconstructive Surgery—Global Open. The study compares Renuvion’s Helium Plasma Technology with InMode’s Bipolar RF System following liposuction…
LEAP Consulting Launches Practice to Aid Labs in FDA LDT Compliance
LEAP Consulting Group, a specialized digital consultancy for the clinical laboratory sector, is thrilled to introduce a new service designed to assist CLIA-certified labs in navigating the FDA’s updated requirements under the LDT Final Rule announced in May 2024. This…
Ontrak Health Previews Q2 2024 Financial Results
Ontrak, Inc. (NASDAQ: OTRK), a leader in AI-powered and technology-driven behavioral healthcare, today released its expected financial results for the second quarter ending June 30, 2024. These results are pending final analysis of debt classification by management. Management Commentary Brandon…
AN2 Therapeutics Updates on EBO-301 Study of Epetraborole for MAC Lung Disease
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company specializing in novel small molecule therapies from its boron chemistry platform, today announced topline results from the Phase 2 portion of the EBO-301 Phase 2/3 study. This study evaluates the efficacy of…